🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. Cutting balloon followed by paclitaxel coated balloon

    Hospital Authority, Hong Kong

    Dialysis Access Malfunction

    phase 2 other completed

    1 trial

  2. Cyclobenzaprine HCl

    Tonix Pharmaceuticals Holding

    Acute Stress Reaction

    phase 2 small molecule active

    1 trial

  3. Cytarabine (Phase 1 only)

    Actinium Pharmaceuticals

    AML

    phase 2 small molecule completed

    1 trial

  4. Cytovir-ADV

    United Therapeutics Europe Ltd

    ADV Infection Post Allo-HSCT

    phase 2 mab completed

    1 trial

  5. DARZALEX 20 mg/mL concentrate for solution for infusion, DARZALEX 1800 mg solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, VELCADE 3.5 mg powder for solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, Venetoclax, DEXAMETHASONE

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  6. DARZALEX 20 mg/mL concentrate for solution for infusion, Kyprolis 60 mg powder for solution for infusion, Empliciti 400 mg powder for concentrate for solution for infusion., Dexamethason CF 20 mg/ml, injectievloeistof, Dexamethasone 2mg Tablets, VELCADE 3.5 mg powder for solution for injection, DARZALEX 1800 mg solution for injection, Dexamethason 4 mg JENAPHARM®, CC-92480, Dexamethason-ratiopharm® 4 mg Tabletten, CC-92480, CC-92480

    Celgene Europe Limited

    Relapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM (NDMM)

    phase 2 small molecule active

    1 trial

  7. DASATINIB, Placebo

    The George Institute

    Asymptomatic patients with recent HIV-1 infection

    phase 2 small molecule active

    1 trial

  8. DEGARELIX ACETATE, ENZALUTAMIDE, DEGARELIX, ENZALUTAMIDE, DAROLUTAMIDE, RELUGOLIX, -, ENZALUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, Pluvicto 1 000 MBq/mL solution for injection/infusion, APALUTAMIDE

    Novartis Pharmaceuticals

    PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)

    phase 2 small molecule active

    1 trial

  9. DESF

    Aquestive Therapeutics

    Allergic Reaction

    phase 2 small molecule completed

    1 trial

  10. DEXAMETHASONE SODIUM PHOSPHATE, VELCADE 3.5 mg powder for solution for injection, DARATUMUMAB, CYCLOPHOSPHAMIDE

    Janssen-Cilag International N.V.

    Amyloid Light Chain Amyloidosis

    phase 2 small molecule active

    1 trial

  11. DFV890, DFV890, Placebo to MAS825 100 mg/1 mL Solution for Injection, Placebo to DFV890 10 mg and 25 mg film-coated tablet, MAS825

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease

    phase 2 small molecule active

    1 trial

  12. DIPHENHYDRAMINE HYDROCHLORIDE, PF-06835375 Injection

    Pfizer Australia Pty Ltd

    Primary immune thrombocytopenia

    phase 2 small molecule active

    1 trial

  13. DOCETAXEL , AVELUMAB, FLUOROURACIL , OXALIPLATIN , CALCIUM FOLINATE

    The George Institute

    Resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC)

    phase 2 small molecule active

    1 trial

  14. DONEPEZIL ARROW 5 mg, comprimé pelliculé, The placebo has the same container composition as the investigational medicinal product (exception of the active substance) and is manufactured by the same manufacturer (pui of the brest university hospital) according to the same procedures as the investigational medicinal product. the active substance is lactose monohydrate, ARICEPT 5 mg, comprimé pelliculé, DONEPEZIL BIOGARAN 5 mg, comprimé pelliculé

    Pari Pharma GmbH

    Anorexia nervosa

    phase 2 small molecule active

    1 trial

  15. DOR/ISL

    Merck KGaA, Darmstadt, Germany

    HIV-1 Infection

    phase 2 small molecule completed

    1 trial

  16. DS-8201a

    AstraZeneca AB

    Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology

    phase 2 small molecule active

    1 trial

  17. DT-168

    Lxo Ireland Designated Activity Company

    Fuchs Endothelial Corneal Dystrophy

    phase 2 small molecule active

    1 trial

  18. DT-216P2

    Lxo Ireland Designated Activity Company

    Friedreich Ataxia

    phase 2 small molecule active

    2 trials

  19. Daptomycin for Injection

    Merck KGaA, Darmstadt, Germany

    Bacteremia

    phase 2 small molecule completed

    1 trial

  20. Daratumumab Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 2 small molecule active

    2 trials

  21. Darleukin, Fibromun

    Philogen S.p.A.

    Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.

    phase 2 small molecule active

    1 trial

  22. Description and Composition of the Placebo • Placebo oil solution matching the Cannabis Extract Avextra 10/10 Solution. • Pharmaceutical form: solution (oil) • Route of administration: oral • Storage: Store tightly closed below 25°C and protected from light like the verum form. • Country of origin: Italy., Cannabis Extract Avextra 10/10 Solution

    Fondazione Telethon ETS

    Patients with advanced oncologic disease receiving active treatment with WHO level II or III opioids and adjuvants therapies

    phase 2 small molecule active

    1 trial

  23. Desmopressin Injection

    United Therapeutics Europe Ltd

    Stroke, Acute

    phase 2 small molecule completed

    1 trial

  24. Dexamethason 4 mg JENAPHARM®, Dexamethasone Tablets BP 2.0mg, CRISANTASPASE, Dexamethason 0,5 mg JENAPHARM®, Vincristine Sulfate 1 mg/ml solution for injection, Oncaspar 750 U/ml powder for solution for injection/infusion., Dexamethasone 3.3 mg/mL Solution for injection, MITOXANTRONE HYDROCHLORIDE, BESPONSA 1 mg powder for concentrate for solution for infusion

    Pfizer Australia Pty Ltd

    Acute Lymphoblastic Leukemia (ALL)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources